# STING agonist payloads

Source: https://onco.cc/terms/sting-agonist-payloads/  
OnCo record `sting-agonist-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads activate an internal alarm that can bring immune cells into action. Antibody delivery aims to trigger the alarm near tumors while limiting activation elsewhere.

## Summary

STING is an intracellular sensor pathway involved in innate immunity. XMT-2056 is a HER2-directed conjugate whose STING agonist activated cancer cells and tumor-resident immune cells in preclinical studies. Its development study must be distinguished from its human trial, which the registry now lists as terminated. STING activation is not equivalent to TLR activation, and tumor-directed delivery does not guarantee freedom from systemic inflammation.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: Immunosynthen; XMT-2056 payload

## Sources

- XMT-2056 preclinical pharmacology (2025): https://doi.org/10.1158/1078-0432.CCR-24-2449
- STING agonist conjugate platform development (2023): https://doi.org/10.1021/acs.jmedchem.3c00907
- ClinicalTrials.gov: NCT05514717: https://clinicaltrials.gov/study/NCT05514717

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune-stimulating antibody conjugate (ISAC)](https://onco.cc/technologies/immune-stimulating-adc/), [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/sting-agonist-payloads.json